SLLN-15

发表于由

上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白，专注于信号通路和疾病研究领域。

SLLN-15 

SLLN-15 是一个口服有效的、选择性的、有效的 自噬 (autophagy) 增强剂，可激活三阴乳腺癌细胞的自噬。

SLLN-15

SLLN-15 Chemical Structure

CAS No. : 2403650-93-9

规格 是否有货
100 mg   询价  
250 mg   询价  
500 mg   询价  

* Please select Quantity before adding items.

生物活性

SLLN-15 is an oral active, selective and potent enhancer of autophagy that activates cytostatic macroautophagy/autophagy in triple-negative breast cancer (TNBC)[1].

体外研究
(In Vitro)

SLLN-15 (0, 1, 5, 10, 25 μM) treatment for 24 h markedly decreases overall cell viability of breast cancer cells in a dose-dependent manner[1].
SLLN-15 (100 nM and 1000 nM, 7 days) is able to equally inhibit the colony formation abilities of several breast cancer cell lines[1].
Overall, SLLN-15 induces a dose-dependent anti-proliferative activity in the TNBC cell lines MDA-MB-231 and BT-20 via induction of autophagy and autophagic flux. This induction is associated with a selective inhibition of AKT-MTOR signaling.

上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability Assay[1]

Cell Line: TNBC cell lines BT-20 and MDA-MB-231.
Concentration: 0, 1, 5, 10, 25 μM.
Incubation Time: 24 hours.
Result: Inhibited the proliferation of two TNBC cell lines, BT-20 and MDA-MB-231.

Cell Viability Assay[1]

Cell Line: TNBC cell lines (MDA-MB-231, BT-20, 4T1, MDA-MB-468), MCF-7 (ERBB2–), SKBR-3 (ERBB2+) and HEK293T.
Concentration: 100 nM and 1000 nM.
Incubation Time: 7 days.
Result: Equally inhibited the colony formation abilities of several breast cancer cell lines.

体内研究
(In Vivo)

SLLN-15 (30mg/kg, PO, 3 times a week) not only inhibits the growth of TNBC in animal model, but also TNBC cell progression to metastases[1].
Overall, oral SLLN-15 reveals a potent anticancer and anti-metastatic activity in mice bearing TNBC[1].

上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: BALB/c mice or SCID mice transplanted with mouse mammary carcinoma 4T1 cells and human breast adenocarcinoma MDA-MB-231 cells (1 X 106 cells/ each mouse)[1]
Dosage: 30mg/kg.
Administration: PO, 3 times a week for 40 days.
Result: Tumor allografts grew at a slower rate compared to control groups.
Significant inhibition of the number of lung metastases as visualized.

分子量

507.35

Formula

C19H23N7Se2
CAS 号

2403650-93-9
运输条件

Room temperature in continental US; may vary elsewhere.
储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.
参考文献

  • [1]. Chang CH, et al. A novel orally available seleno-purine molecule suppresses triple-negative breast cancer cell proliferation and progression to metastasis by inducing cytostatic autophagy. Autophagy. 2019 Mar 1:1-15.

所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务